Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study

导出原文传递

翻译打印收藏纠错

作者： Albers, Frank C. ^[1] ; Muellerova, Hana ^[2] ; Gunsoy, Necdet B. ^[3] ; Shin, Ji-Yeon ^[4] ; Nelsen, Linda M. ^[5] ; Bradford, Eric S. ^[6] ; Cockle, Sarah M. ^[7] ; Suruki, Robert Y.

作者单位： GSK, Seoul, South Korea ^[1] GSK, Value Evidence & Outcomes, Collegeville, PA USA ^[2] GSK House, Value Evidence & Outcomes, Brentford, Middx, England ^[3] GSK, Clin Stat, Stockley Pk, Uxbridge, Middx, England ^[4] GSK, Resp Med Franchise, 5 Moore Dr,POB 13398, Res Triangle Pk, NC 27709 USA ^[5] GSK, Worldwide Epidemiol, Res Triangle Pk, NC USA ^[6] GSK, Real World Evidence, Stockley Pk, Uxbridge, Middx, England ^[7]

关键词 Endotype mepolizumab observational study omalizumab phenotype reslizumab treatment eligibility

发布时间 2018-12-19

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交